Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com
PDS0101 Plus Pembrolizumab Under Further Evaluation in HPV16+ HNSCC
October 4th 2022The FDA has agreed on key elements of the clinical program to support the biologic license application for the combination of PDS0101 and pembrolizumab for the treatment of unresectable, recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma.
Read More
Talazoparib/Enzalutamide Combo Meets rPFS End Point in Untreated Metastatic CRPC
October 4th 2022The addition of talazoparib to enzalutamide produced a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs enzalutamide plus placebo in previously untreated patients with metastatic castration-resistant prostate cancer, with or without homologous recombination repair gene mutations.
Read More
Rucaparib Meets rPFS End Point in BRCA/ATM-Mutated mCRPC
October 3rd 2022Single-agent rucaparib significantly improved radiographic progression-free survival vs chemotherapy or second-line androgen deprivation therapy in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer harboring BRCA or ATM mutations.
Read More
FDA Grants Orphan Drug Designation to SynKIR-110 for Mesothelin-Expressing Mesothelioma
September 28th 2022The FDA has granted an orphan drug designation to SynKIR-110, a first-in-class KIR-CAR T-cell immunotherapy candidate, for the treatment of patients with mesothelin-expressing mesothelioma.
Read More
Rituximab Maintenance Following First-line BR/R-CHOP Offers Significant Real-World Benefits in MCL
September 23rd 2022Maintenance treatment with rituximab following first-line treatment with rituximab plus bendamustine or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone produced an overall survival benefit in older patients with mantle cell lymphoma.
Read More
Dostarlimab Provides Survival Benefits in dMMR Endometrial Cancer and Other Solid Tumors
September 22nd 2022Single-agent dostarlimab showcased durable antitumor activity in patients with mismatch repair–deficient endometrial cancer and other solid tumors, with landmark estimates at various time points underscoring stable progression-free survival benefits in responders.
Read More
China Green Lights Olaparib for First-line Maintenance in HRD+ Advanced Ovarian Cancer
September 22nd 2022Olaparib plus bevacizumab was approved in China as a first-line maintenance treatment for homologous recombination deficiency–positive ovarian cancer following a response to platinum-based chemotherapy plus bevacizumab.
Read More
EphrinB2 Emerges as Targetable Option in Urothelial Carcinoma
September 20th 2022Treatment with soluble EphB4-human serum albumin plus pembrolizumab elicited synergistic activity and an improved overall survival and objective response rate compared with historical data for PD-1/PD-L1 monotherapy in patients with platinum-refractory metastatic urothelial carcinoma.
Read More
Axi-cel Receives Positive Opinion from EU for DLBCL/HGBL
September 19th 2022The European Medicines Agency Committee for Medicinal Products for Human Use has granted a positive opinion for axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma and high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
Read More
NVG-111 Generates Early Efficacy With Manageable Safety in Relapsed/Refractory CLL, MCL
September 14th 2022The ROR1-targeting bispecific T-cell engager NVG-111 elicited promising responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.
Read More
The decline of prostate-specific antigen following treatment with lutetium Lu 177 vipivotide tetraxetan plus standard of care was linked with prolonged radiographic progression-free survival and overall survival in patients with progressive prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.
Read More
Nivolumab/Ipilimumab Boosting Following Nivolumab Monotherapy Increases Responses in Advanced RCC
September 11th 2022A tailored approach utilizing the combination of nivolumab and ipilimumab as an immunotherapeutic boost following induction with single-agent nivolumab improved responses in the first and second line for patients with advanced renal cell carcinoma.
Read More
Lasofoxifene Improves Responses Vs Fulvestrant in ESR1-Mutated, ER+/HER2- Metastatic Breast Cancer
September 10th 2022Single-agent lasofoxifene did not produce a statistically significant improvement in progression-free survival vs fulvestrant for patients with estrogen receptor–positive, HER2-negative metastatic breast cancer harboring ESR1 mutations.
Read More
FDA Approves Eflapegrastim for Chemo-Induced Neutropenia
September 9th 2022The FDA has approved eflapegrastim-xnst injection to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia.
Read More
Second-line Ramucirumab Showcases Survival Benefits in HCC, Irrespective of Extrahepatic Spread
September 7th 2022Second-line treatment with ramucirumab produced an overall survival benefit vs placebo in Chinese patients with hepatocellular carcinoma, irrespective of the presence of extrahepatic spread, according to findings from an exploratory analysis of the phase 3 REACH and REACH-2 trials.
Read More
FDA Approves Pegfilgrastim Biosimilar for Febrile Neutropenia
September 6th 2022The FDA has approved the biosimilar pegfilgrastim for use in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Read More
Vopratelimab Plus Pimivalimab Fails to Meet Tumor Reduction End Point in Select Metastatic NSCLC
August 31st 2022The addition of vopratelimab to pimivalimab did not elicit a significant mean percent change of baseline tumor size in all measurable lesions vs pimivalimab alone in patients with immunotherapy-naïve, metastatic non–small cell lung cancer who were positive for the TISvopra predictive biomarker.
Read More